Researchers from Nanjing University of Traditional Chinese Medicine reported the discovery and preclinical characterization of fluorine-substituted selective estrogen receptor degraders (SERDs) as potential candidates for the treatment of estrogen receptor (ER)-positive breast cancer.
Haisco Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon binding moiety covalently coupled to poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) targeting moiety through a linker acting as PARP-1 degradation inducers reported to be useful for the treatment of cancer.
Veracyte Inc. reported that its Prosigna breast cancer assay significantly reduced the use of chemotherapy in patients with high-risk, early-stage disease at the European Society for Medical Oncology 2023 in Berlin this week. The findings came from the EMIT study, a prospective, multi-year, population-based study in women in Norway that is assessing the impact of the Prosigna test on treatment decisions and outcomes.
Researchers from TYK Medicines Inc. presented the discovery and preclinical evaluation of a new cyclin-dependent kinase 274/6 (CDK2/4/6) inhibitor, TY-0540, being developed as an anticancer agent.
The U.S. Preventive Services Task Force (USPSTF) is proposing to lower the age of onset of regular breast cancer screening to 40 years, a massive jump of 10 years over the current recommended age of 50 years. While this is just a draft proposal, analysts who track the medical device industry say that medical imaging manufacturers, such as Marlborough, Mass.-based Hologic Inc., could see a significant uptick in demand for their systems, a much-needed boost as the drop in demand incurred by the COVID-19 pandemic comes to an end.
In the latest deal from the burgeoning antibody-drug conjugate (ADC) space, Eisai Co. Ltd. and privately held Bliss Biopharmaceutical (Hangzhou) Co. Ltd. reached a development and commercialization agreement that could be worth up to $2 billion. The massive collaboration is the eighth largest so far this year and one of three that involve ADCs in the year’s top 10 deals.
Roche AG acquired global rights to Zion Pharma Ltd.’s lead program, ZN-A-1041, an orally administered selective tyrosine kinase inhibitor that is designed to penetrate the blood-brain barrier and can prevent and treat brain metastases in HER2-positive metastatic breast cancer patients.
IL-18 is a pro-inflammatory cytokine that triggers IFN-γ production and increases T- and NK-cell activity. IL-18’s effects are blocked by IL-18 binding protein (IL-18BP), an endogenous protein that binds to IL-18 with high affinity and that is highly present in the tumor microenvironment (TME).
In the latest deal from the burgeoning antibody-drug conjugate (ADC) space, Eisai Co. Ltd. and privately held Bliss Biopharmaceutical (Hangzhou) Co. Ltd. reached a development and commercialization agreement that could be worth up to $2 billion. The massive collaboration is the eighth largest so far this year and one of three that involve ADCs in the year’s top 10 deals. The year’s biggest, according to BioWorld statistics, is the partnership extension between Evotec SE and Bristol Myers Squibb Co. to identify neurodegenerative disease therapies for eight years. The other ADC deals involve Synaffix BV, which signed a $2 billion pact in January with Amgen Inc., and a $2.2 billion expanded deal in February with Macrogenics Inc.
